Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ryu, Ka-Young | - |
dc.contributor.author | Lee, Hyun-Ju | - |
dc.contributor.author | Woo, Hanwoong | - |
dc.contributor.author | Kang, Ri-Jin | - |
dc.contributor.author | Han, Kyung-Min | - |
dc.contributor.author | Park, HyunHee | - |
dc.contributor.author | Lee, Sang Min | - |
dc.contributor.author | Lee, Ju-Young | - |
dc.contributor.author | Jeong, Yoo Joo | - |
dc.contributor.author | Nam, Hyun-Wook | - |
dc.contributor.author | Nam, Youngpyo | - |
dc.contributor.author | Hoe, Hyang-Sook | - |
dc.date.accessioned | 2019-12-12T08:35:57Z | - |
dc.date.available | 2019-12-12T08:35:57Z | - |
dc.date.created | 2019-11-07 | - |
dc.date.issued | 2019-10 | - |
dc.identifier.citation | Journal of Neuroinflammation, v.16, no.1 | - |
dc.identifier.issn | 1742-2094 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11750/10925 | - |
dc.description.abstract | Background: The FDA-approved small-molecule drug dasatinib is currently used as a treatment for chronic myeloid leukemia (CML). However, the effects of dasatinib on microglial and/or astrocytic neuroinflammatory responses and its mechanism of action have not been studied in detail. Methods: BV2 microglial cells, primary astrocytes, or primary microglial cells were treated with dasatinib (100 or 250 nM) or vehicle (1% DMSO) for 30 min or 2 h followed by lipopolysaccharide (LPS; 200 ng/ml or 1 μg/ml) or PBS for 5.5 h. RT-PCR, real-time PCR; immunocytochemistry; subcellular fractionation; and immunohistochemistry were subsequently conducted to determine the effects of dasatinib on LPS-induced neuroinflammation. In addition, wild-type mice were injected with dasatinib (20 mg/kg, intraperitoneally (i.p.) daily for 4 days or 20 mg/kg, orally administered (p.o.) daily for 4 days or 2 weeks) or vehicle (4% DMSO + 30% polyethylene glycol (PEG) + 5% Tween 80), followed by injection with LPS (10 mg/kg, i.p.) or PBS. Then, immunohistochemistry was performed, and plasma IL-6, IL-1β, and TNF-α levels were analyzed by ELISA. Results: Dasatinib regulates LPS-induced proinflammatory cytokine and anti-inflammatory cytokine levels in BV2 microglial cells, primary microglial cells, and primary astrocytes. In BV2 microglial cells, dasatinib regulates LPS-induced proinflammatory cytokine levels by regulating TLR4/AKT and/or TLR4/ERK signaling. In addition, intraperitoneal injection and oral administration of dasatinib suppress LPS-induced microglial/astrocyte activation, proinflammatory cytokine levels (including brain and plasma levels), and neutrophil rolling in the brains of wild-type mice. Conclusions: Our results suggest that dasatinib modulates LPS-induced microglial and astrocytic activation, proinflammatory cytokine levels, and neutrophil rolling in the brain. © 2019 The Author(s). | - |
dc.language | English | - |
dc.publisher | BioMed Central | - |
dc.title | Dasatinib regulates LPS-induced microglial and astrocytic neuroinflammatory responses by inhibiting AKT/STAT3 signaling | - |
dc.type | Article | - |
dc.identifier.doi | 10.1186/s12974-019-1561-x | - |
dc.identifier.wosid | 000493094400001 | - |
dc.identifier.scopusid | 2-s2.0-85074174356 | - |
dc.type.local | Article(Overseas) | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.citation.publicationname | Journal of Neuroinflammation | - |
dc.contributor.nonIdAuthor | Ryu, Ka-Young | - |
dc.contributor.nonIdAuthor | Lee, Hyun-Ju | - |
dc.contributor.nonIdAuthor | Woo, Hanwoong | - |
dc.contributor.nonIdAuthor | Kang, Ri-Jin | - |
dc.contributor.nonIdAuthor | Han, Kyung-Min | - |
dc.contributor.nonIdAuthor | Park, HyunHee | - |
dc.contributor.nonIdAuthor | Lee, Sang Min | - |
dc.contributor.nonIdAuthor | Lee, Ju-Young | - |
dc.contributor.nonIdAuthor | Jeong, Yoo Joo | - |
dc.contributor.nonIdAuthor | Nam, Hyun-Wook | - |
dc.contributor.nonIdAuthor | Nam, Youngpyo | - |
dc.contributor.nonIdAuthor | Hoe, Hyang-Sook | - |
dc.identifier.citationVolume | 16 | - |
dc.identifier.citationNumber | 1 | - |
dc.identifier.citationTitle | Journal of Neuroinflammation | - |
dc.type.journalArticle | Article | - |
dc.description.isOpenAccess | Y | - |
dc.subject.keywordAuthor | LPS | - |
dc.subject.keywordAuthor | Neuroinflammation | - |
dc.subject.keywordAuthor | STAT3 | - |
dc.subject.keywordAuthor | AKT | - |
dc.subject.keywordAuthor | Microglia | - |
dc.subject.keywordAuthor | Astrocytes | - |
dc.subject.keywordPlus | KAPPA-B ACTIVATION | - |
dc.subject.keywordPlus | TYROSINE KINASE INHIBITORS | - |
dc.subject.keywordPlus | CHRONIC MYELOID-LEUKEMIA | - |
dc.subject.keywordPlus | C-ABL KINASE | - |
dc.subject.keywordPlus | MOUSE MODEL | - |
dc.subject.keywordPlus | INFLAMMATORY RESPONSES | - |
dc.subject.keywordPlus | NLRP3 INFLAMMASOME | - |
dc.subject.keywordPlus | IMATINIB | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordPlus | APOPTOSIS | - |
dc.contributor.affiliatedAuthor | Ryu, Ka-Young | - |
dc.contributor.affiliatedAuthor | Lee, Hyun-Ju | - |
dc.contributor.affiliatedAuthor | Woo, Hanwoong | - |
dc.contributor.affiliatedAuthor | Kang, Ri-Jin | - |
dc.contributor.affiliatedAuthor | Han, Kyung-Min | - |
dc.contributor.affiliatedAuthor | Park, HyunHee | - |
dc.contributor.affiliatedAuthor | Lee, Sang Min | - |
dc.contributor.affiliatedAuthor | Lee, Ju-Young | - |
dc.contributor.affiliatedAuthor | Jeong, Yoo Joo | - |
dc.contributor.affiliatedAuthor | Nam, Hyun-Wook | - |
dc.contributor.affiliatedAuthor | Nam, Youngpyo | - |
dc.contributor.affiliatedAuthor | Hoe, Hyang-Sook | - |